Molecular testing in myelodysplastic syndromes for the practicing oncologist: Will the progress fulfill the promise?

Aziz Nazha, Mikkael A. Sekeres, Steven D. Gore, Amer M. Zeidan

Research output: Contribution to journalArticle

Abstract

Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters. Newer technologies with next-generation targeted deep sequencing and whole-genome and-exome sequencing have identified several recurrent mutations that play a vital role in the pathophysiology of MDS and the impact of these genetic changes on disease phenotype. Equally important, well-annotated databases of MDS patients with paired clinicopathologic and genetic data have enabled better understanding of the independent prognostic impact of several molecular mutations on important clinical endpoints such as overall survival and probability of leukemic progression. Cumulative evidence suggests that genomic data can also be used clinically to aid with the diagnosis, prognosis, prediction of response to specific therapies, and the development of novel and rationally targeted therapies. However, the optimal use of this mutational profiling remains a work in progress and currently there is no standard set of genes or techniques that are recommended for routine use in the clinic. In this review, we discuss the genomic revolution and its impact on our understanding of MDS biology and risk stratification.We also discuss the current role and the challenges of the application of genetic mutational data into daily clinical practice and how future research could help improve the prognostication precision and specific therapy selection for patients with MDS.

Original languageEnglish (US)
Pages (from-to)1069-1076
Number of pages8
JournalOncologist
Volume20
Issue number9
DOIs
StatePublished - Jul 20 2015
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Mutation
Exome
High-Throughput Nucleotide Sequencing
Hematologic Neoplasms
Therapeutics
Epigenomics
Patient Selection
Oncologists
Genome
Databases
Technology
Phenotype
Survival
Genes

Keywords

  • Biomarkers
  • MDS
  • Molecular testing
  • Mutations
  • Myelodysplastic syndromes
  • Prognostication

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular testing in myelodysplastic syndromes for the practicing oncologist : Will the progress fulfill the promise? / Nazha, Aziz; Sekeres, Mikkael A.; Gore, Steven D.; Zeidan, Amer M.

In: Oncologist, Vol. 20, No. 9, 20.07.2015, p. 1069-1076.

Research output: Contribution to journalArticle

Nazha, Aziz ; Sekeres, Mikkael A. ; Gore, Steven D. ; Zeidan, Amer M. / Molecular testing in myelodysplastic syndromes for the practicing oncologist : Will the progress fulfill the promise?. In: Oncologist. 2015 ; Vol. 20, No. 9. pp. 1069-1076.
@article{78e159da191640bb85d84fa3a6c46fc3,
title = "Molecular testing in myelodysplastic syndromes for the practicing oncologist: Will the progress fulfill the promise?",
abstract = "Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters. Newer technologies with next-generation targeted deep sequencing and whole-genome and-exome sequencing have identified several recurrent mutations that play a vital role in the pathophysiology of MDS and the impact of these genetic changes on disease phenotype. Equally important, well-annotated databases of MDS patients with paired clinicopathologic and genetic data have enabled better understanding of the independent prognostic impact of several molecular mutations on important clinical endpoints such as overall survival and probability of leukemic progression. Cumulative evidence suggests that genomic data can also be used clinically to aid with the diagnosis, prognosis, prediction of response to specific therapies, and the development of novel and rationally targeted therapies. However, the optimal use of this mutational profiling remains a work in progress and currently there is no standard set of genes or techniques that are recommended for routine use in the clinic. In this review, we discuss the genomic revolution and its impact on our understanding of MDS biology and risk stratification.We also discuss the current role and the challenges of the application of genetic mutational data into daily clinical practice and how future research could help improve the prognostication precision and specific therapy selection for patients with MDS.",
keywords = "Biomarkers, MDS, Molecular testing, Mutations, Myelodysplastic syndromes, Prognostication",
author = "Aziz Nazha and Sekeres, {Mikkael A.} and Gore, {Steven D.} and Zeidan, {Amer M.}",
year = "2015",
month = "7",
day = "20",
doi = "10.1634/theoncologist.2015-0067",
language = "English (US)",
volume = "20",
pages = "1069--1076",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Molecular testing in myelodysplastic syndromes for the practicing oncologist

T2 - Will the progress fulfill the promise?

AU - Nazha, Aziz

AU - Sekeres, Mikkael A.

AU - Gore, Steven D.

AU - Zeidan, Amer M.

PY - 2015/7/20

Y1 - 2015/7/20

N2 - Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters. Newer technologies with next-generation targeted deep sequencing and whole-genome and-exome sequencing have identified several recurrent mutations that play a vital role in the pathophysiology of MDS and the impact of these genetic changes on disease phenotype. Equally important, well-annotated databases of MDS patients with paired clinicopathologic and genetic data have enabled better understanding of the independent prognostic impact of several molecular mutations on important clinical endpoints such as overall survival and probability of leukemic progression. Cumulative evidence suggests that genomic data can also be used clinically to aid with the diagnosis, prognosis, prediction of response to specific therapies, and the development of novel and rationally targeted therapies. However, the optimal use of this mutational profiling remains a work in progress and currently there is no standard set of genes or techniques that are recommended for routine use in the clinic. In this review, we discuss the genomic revolution and its impact on our understanding of MDS biology and risk stratification.We also discuss the current role and the challenges of the application of genetic mutational data into daily clinical practice and how future research could help improve the prognostication precision and specific therapy selection for patients with MDS.

AB - Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters. Newer technologies with next-generation targeted deep sequencing and whole-genome and-exome sequencing have identified several recurrent mutations that play a vital role in the pathophysiology of MDS and the impact of these genetic changes on disease phenotype. Equally important, well-annotated databases of MDS patients with paired clinicopathologic and genetic data have enabled better understanding of the independent prognostic impact of several molecular mutations on important clinical endpoints such as overall survival and probability of leukemic progression. Cumulative evidence suggests that genomic data can also be used clinically to aid with the diagnosis, prognosis, prediction of response to specific therapies, and the development of novel and rationally targeted therapies. However, the optimal use of this mutational profiling remains a work in progress and currently there is no standard set of genes or techniques that are recommended for routine use in the clinic. In this review, we discuss the genomic revolution and its impact on our understanding of MDS biology and risk stratification.We also discuss the current role and the challenges of the application of genetic mutational data into daily clinical practice and how future research could help improve the prognostication precision and specific therapy selection for patients with MDS.

KW - Biomarkers

KW - MDS

KW - Molecular testing

KW - Mutations

KW - Myelodysplastic syndromes

KW - Prognostication

UR - http://www.scopus.com/inward/record.url?scp=84940659678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940659678&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0067

DO - 10.1634/theoncologist.2015-0067

M3 - Article

C2 - 26194858

AN - SCOPUS:84940659678

VL - 20

SP - 1069

EP - 1076

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -